Sumanirol

Из Википедије, слободне енциклопедије
Sumanirol
(IUPAC) ime
(R)-5,6-dihidro-5-(metilamino)-4H-imidazo[4,5,1-ij]hinolin-2(1H)-on
Klinički podaci
Identifikatori
CAS broj 179386-43-7
179386-44-8 (maleat)
ATC kod nije dodeljen
PubChem[1][2] 9818479
ChemSpider[3] 7994229
UNII 3E93IV1U45 YesY
Hemijski podaci
Formula C11H13N3O 
Mol. masa 203,240 g/mol
SMILES eMolekuli & PubHem
Farmakoinformacioni podaci
Trudnoća  ?
Pravni status

Sumanirol (PNU-95,666) je visoko selektivni pun agonist D2 receptora. On je prvi otkriveni agonist iz te grupe.[4][5][6]

Sumanirol je razvijen za lečenje Parkinsonove bolesti i sindroma nemirnih nogu. Mada on nije odobren za kliničku upotrebu,[7][8] on je korisno oruđe za bazna istraživanja neurobioloških mehanizama koji su bazirani na modu dejstva dopaminskog D2 receptora (vs. D1, D3, D4, i D5 receptora).[6]

Reference[уреди]

  1. ^ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.“. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519.  edit
  2. ^ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities“. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1. 
  3. ^ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining“. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846.  edit
  4. ^ Romero AG, et al. Synthesis of the selective D2 receptor agonist PNU-95666E from D-phenylalanine using a sequential oxidative cyclization strategy. Journal of Organic Chemistry. 1997; 62(19):6582.
  5. ^ McCall RB, Lookingland KJ, Bédard PJ, Huff RM (September 2005). „Sumanirole, a highly dopamine D2-selective receptor agonist: in vitro and in vivo pharmacological characterization and efficacy in animal models of Parkinson's disease“. The Journal of Pharmacology and Experimental Therapeutics 314 (3): 1248–56. DOI:10.1124/jpet.105.084202. PMID 15980060. 
  6. ^ а б Weber M, Chang WL, Breier MR, Yang A, Millan MJ, Swerdlow NR (March 2010). „The effects of the dopamine D2 agonist sumanirole on prepulse inhibition in rats“. European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology 20 (6): 421–425. DOI:10.1016/j.euroneuro.2010.02.011. PMC 2864324. PMID 20346635. 
  7. ^ Barone P, Lamb J, Ellis A, Clarke Z (March 2007). „Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease“. Movement Disorders : Official Journal of the Movement Disorder Society 22 (4): 483–9. DOI:10.1002/mds.21191. PMID 17115380. 
  8. ^ Garcia-Borreguero D, Winkelman J, Adams A, Ellis A, Morris M, Lamb J, Layton G, Versavel M (March 2007). „Efficacy and tolerability of sumanirole in restless legs syndrome: a phase II, randomized, double-blind, placebo-controlled, dose-response study“. Sleep Medicine 8 (2): 119–27. DOI:10.1016/j.sleep.2006.05.018. PMID 17239657. 

Spoljašnje veze[уреди]